Experiences of sharing results of community based serosurvey with participants in a district of Maharashtra, India.

Abstract

A growing number of organisations, including medical associations, recommend that research subjects should be given the option of being informed about the general outcome and results of the study. We recently completed a study involving nine serosurveys from 2018 to 2020 in five districts of India among three age groups (children 9 months to < 5 years; 5 to < 15 years of age, and women 15 to < 50 years of age before and after the measles and rubella (MR) vaccination campaigns). In Palghar district of Maharashtra all individuals in 30 selected clusters were enumerated, and 13 individuals per age group were randomly sampled. We established the procedures to return the results to the respondents for each stage of the survey. Of the 1,166 individuals selected for the measles and rubella serosurvey, 971 (83%) agreed to participate and were enrolled. Participants were informed that they will only be contacted if they test seronegative for measles and/or rubella antibodies. Overall, 140 individuals enrolled in the survey tested seronegative for IgG antibodies to measles and/or rubella viruses; were provided the reports and informed to seek medical advice. Upon follow up by phone, 10% (14) of the 140 participants reported to have been vaccinated. In this paper we discuss the procedures, experiences and considerations in returning results to participants in a community-based measles and rubella serosurvey. Although the lessons learned are specific to post measles-rubella vaccine campaign serosurvey in India, they might be helpful to those contemplating sharing results to participants of large scale survey settings.

• Authors: Neha Salvi, Krishna Chaaithanya Itta, Abhishek Lachyan, Alvira Z Hasan, Christine Prosperi, Muthusamy Santhosh Kumar, Jeromie Wesley Vivian Thangaraj, Ojas Kaduskar, Vaishali Bhatt, Gajanan N Sapkal, Manoj Murhekar, Nivedita Gupta, Sanjay Mehendale, Kyla Hayford, William J Moss, Sanjay Chauhan, Ragini Kulkarni
• Journal: PloS one (PLoS One) Vol. 17 Issue 8 Pg. e0271920 ( 2022) ISSN: 1932-6203 [Electronic] United States
• PMID: 35925959 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Viral
• Measles Vaccine
• Measles-Mumps-Rubella Vaccine
• Rubella Vaccine

Topics

• Antibodies, Viral
• Child
• Female
• Humans
• India (epidemiology)
• Infant
• Measles (epidemiology, prevention & control)
• Measles Vaccine (therapeutic use)
• Measles-Mumps-Rubella Vaccine
• Rubella (epidemiology, prevention & control)
• Rubella Vaccine
• Vaccination